AstraZeneca Updates Total Voting Rights and Admits New Shares from Employee Schemes

AstraZeneca ( (GB:AZN) ) has shared an update.

AstraZeneca is a global, science-led biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals, including cardiovascular, renal, metabolism, respiratory, and immunology therapies. Headquartered in Cambridge, U.K., the company markets innovative treatments in more than 125 countries to millions of patients worldwide.

AstraZeneca reported that as of 30 April 2026 its issued share capital with voting rights stands at 1,550,995,630 ordinary shares, with no treasury shares, setting the denominator for shareholder disclosure obligations under U.K. transparency rules. The company also confirmed the admission to trading on the London Stock Exchange’s Main Market of 14,807 additional ordinary shares issued under employee share schemes, which are fully fungible with existing stock and slightly increase the equity base while supporting staff incentive programmes.

These changes formalise the company’s current capital structure for regulatory and investor reporting, helping shareholders assess when they must notify changes in their holdings. The incremental share issuance, conducted under an existing block admission, reflects ongoing use of equity-based compensation without materially diluting existing investors or altering AstraZeneca’s overall market position.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on AZN Stock

According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.

The score is driven primarily by strong fundamentals (growth and profitability) and a constructive earnings outlook with pipeline and guidance support. It is held back by weak technical momentum and a valuation that looks elevated relative to the modest dividend yield, alongside near-term risks (notably Farxiga LOE and China pricing pressure).

To see Spark’s full report on AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals, including cardiovascular, renal, metabolism, respiratory, and immunology therapies. Headquartered in Cambridge, U.K., the company markets innovative treatments in more than 125 countries to millions of patients worldwide.

The company’s diversified portfolio and broad geographic reach position it as a major player in the global healthcare and pharmaceutical industry, with a strategic emphasis on high-growth therapeutic areas and advanced research-led drug development.

Average Trading Volume: 2,670,964

Technical Sentiment Signal: Buy

Current Market Cap: £216.3B

See more insights into AZN stock on TipRanks’ Stock Analysis page.